MX2018004356A - Formulacion de liberacion modificada de naproxeno sodico. - Google Patents
Formulacion de liberacion modificada de naproxeno sodico.Info
- Publication number
- MX2018004356A MX2018004356A MX2018004356A MX2018004356A MX2018004356A MX 2018004356 A MX2018004356 A MX 2018004356A MX 2018004356 A MX2018004356 A MX 2018004356A MX 2018004356 A MX2018004356 A MX 2018004356A MX 2018004356 A MX2018004356 A MX 2018004356A
- Authority
- MX
- Mexico
- Prior art keywords
- naproxen sodium
- pain relief
- release
- naproxen
- hours
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
Landscapes
- Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención es una formulación de naproxeno que tiene un perfil de liberación que proporciona alivio inmediato del dolor equivalente a tomar 440 mg (o 2 comprimidos de 220 mg) de naproxeno sódico y también alivio extendido del dolor durante 24 horas. En particular, la presente invención es una dosis sólida individual que combina una proporción única de un producto de liberación inmediata de naproxeno sódico con una capa de liberación extendida de naproxeno sódico. Más particularmente, la presente invención es un comprimido individual de dos capas que libera inmediatamente 300-320 mg de naproxeno sódico y a partir de entonces gradualmente libera 450-480 mg de naproxeno sódico. Este producto es capaz de proporcionar 24 horas de alivio del dolor cuando se administra como un comprimido de dos capas individuales. El comprimido de dos capas individuales proporciona liberación inmediata (IR) de naproxeno sódico para el alivio inicial del dolor de una capa seguido de la liberación continua del naproxeno sódico remanente de la otra capa para mantener el alivio extendido del dolor hasta 24 horas.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2015/054873 WO2017062027A1 (en) | 2015-10-09 | 2015-10-09 | Modified release formulation of naproxen sodium |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018004356A true MX2018004356A (es) | 2018-05-23 |
Family
ID=54478208
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018004356A MX2018004356A (es) | 2015-10-09 | 2015-10-09 | Formulacion de liberacion modificada de naproxeno sodico. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20180280305A1 (es) |
| EP (1) | EP3359139B1 (es) |
| CN (2) | CN108366969A (es) |
| AU (1) | AU2015411334B2 (es) |
| BR (1) | BR112018007133A2 (es) |
| CA (1) | CA3001288C (es) |
| CR (1) | CR20180209A (es) |
| ES (1) | ES2954452T3 (es) |
| MX (1) | MX2018004356A (es) |
| WO (1) | WO2017062027A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR113993A1 (es) | 2017-12-21 | 2020-07-08 | Faes Farma Sa | Formulación una vez al día de hidrosmina |
| CN114901271A (zh) * | 2019-12-19 | 2022-08-12 | 拜耳医药保健有限责任公司 | 包含萘普生钠滚柱压实颗粒的口服片剂及其制备方法和使用方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1200178B (it) * | 1986-07-23 | 1989-01-05 | Alfa Farmaceutici Spa | Formulazioni galeniche a cessione programmata contenenti farmaci ad attivita' antiflogistica |
| US5609884A (en) * | 1992-08-31 | 1997-03-11 | G. D. Searle & Co. | Controlled release naproxen sodium plus naproxen combination tablet |
| AU5134699A (en) * | 1998-07-24 | 2000-02-14 | Andrix Pharmaceuticals, Inc. | Granule modulating hydrogel system |
| MX2010001789A (es) * | 2007-08-15 | 2010-03-10 | Mcneil Ppc Inc | Regimen de dosificacion de ibuprofeno de liberacion inmediata y liberacion sostenida. |
| EP3090743A1 (en) * | 2008-01-09 | 2016-11-09 | Charleston Laboratories, Inc. | Pharmaceutical compositions for treating headache and eliminating nausea |
| WO2010138441A1 (en) * | 2009-05-28 | 2010-12-02 | Aptapharma, Inc. | Multilayer oral tablets containing a non-steroidal anti-inflammatory drug and/or acetaminophen |
| US20140037725A1 (en) * | 2012-08-01 | 2014-02-06 | Cadila Healthcare Limited | Bilayer pharmaceutical compositions of naproxen |
-
2015
- 2015-10-09 ES ES15791391T patent/ES2954452T3/es active Active
- 2015-10-09 AU AU2015411334A patent/AU2015411334B2/en active Active
- 2015-10-09 CN CN201580085209.5A patent/CN108366969A/zh active Pending
- 2015-10-09 EP EP15791391.4A patent/EP3359139B1/en active Active
- 2015-10-09 CN CN202310629846.0A patent/CN116869951A/zh active Pending
- 2015-10-09 WO PCT/US2015/054873 patent/WO2017062027A1/en active Application Filing
- 2015-10-09 US US15/766,044 patent/US20180280305A1/en not_active Abandoned
- 2015-10-09 MX MX2018004356A patent/MX2018004356A/es unknown
- 2015-10-09 BR BR112018007133A patent/BR112018007133A2/pt not_active Application Discontinuation
- 2015-10-09 CR CR20180209A patent/CR20180209A/es unknown
- 2015-10-09 CA CA3001288A patent/CA3001288C/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN108366969A (zh) | 2018-08-03 |
| CA3001288A1 (en) | 2017-04-13 |
| CN116869951A (zh) | 2023-10-13 |
| CR20180209A (es) | 2018-08-09 |
| AU2015411334A1 (en) | 2018-04-26 |
| WO2017062027A1 (en) | 2017-04-13 |
| US20180280305A1 (en) | 2018-10-04 |
| AU2015411334B2 (en) | 2021-11-18 |
| CA3001288C (en) | 2022-07-19 |
| EP3359139B1 (en) | 2023-06-07 |
| ES2954452T3 (es) | 2023-11-22 |
| EP3359139A1 (en) | 2018-08-15 |
| EP3359139C0 (en) | 2023-06-07 |
| BR112018007133A2 (pt) | 2018-11-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2017000109A (es) | Derivados de feniltriazol sustituido con hidroxialquilo y sus usos | |
| EP4233889A3 (en) | Activin-actrii antagonists and uses for treating myelodysplastic syndrome | |
| MY196173A (en) | Cot Modulators And Methods Of Use Thereof | |
| EP4249055A3 (en) | Tofacitinib oral sustained release dosage forms | |
| EP4349406A3 (en) | Crystalline solid forms of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole for use as a medicament | |
| EA201690107A1 (ru) | Фармацевтическая композиция, содержащая диметилфумарат, для введения в низкой суточной дозе | |
| WO2017037594A3 (zh) | 用于减少局部脂肪的医药组成物及其用途 | |
| BR112017001192A2 (pt) | composições de açúcar para preparação de tabletes por meio de compressão direta | |
| PH12020550815A1 (en) | Delayed release deferiprone tablets and methods of using the same | |
| BR112012020989A2 (pt) | composições veterinárias | |
| MY157673A (en) | Pharmaceutical compositions comprising hydromorphone and naloxone | |
| EA201790726A1 (ru) | Фармацевтическая композиция для лечения язвенного колита | |
| CL2016001094A1 (es) | Silicato de zirconio microporoso para el tratamiento de hipercalemia. | |
| EP4282414A3 (en) | Modified release tablet formulations containing phosphodiesterase inhibitors | |
| BR112018068116A2 (pt) | película transmucosal para administração de montelucaste | |
| WO2014144407A8 (en) | Dual use oral pharmaceutical composition tablets of sulfate salts and methods of use thereof | |
| MY174648A (en) | Formulations of organic compounds | |
| BR112017001000A2 (pt) | composições de açúcar para preparação de comprimidos por compressão direta | |
| MX2018004356A (es) | Formulacion de liberacion modificada de naproxeno sodico. | |
| MX2017004723A (es) | Composicion farmaceutica para usarse en el tratamiento o la prevencion de deficiencias de vitaminas y minerales en pacientes que han sido sometidos a cirugia de derivacion gastrica. | |
| WO2015082590A3 (en) | Bis-mmf derivatives | |
| EA201891886A1 (ru) | Содержащая прегабалин трехслойная таблетка с замедленным высвобождением для перорального приема | |
| MX2022013541A (es) | Composiciones de acido gamma-poliglutamico y zinc. | |
| WO2016072692A3 (ko) | 네크록스를 유효성분으로 함유하는 점막염 예방 또는 치료용 조성물 | |
| WO2016020408A3 (en) | Compounds for preventing ototoxicity |